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CELL-FREE SYNTHESIS OF MEMBRANE 
BOUND POLYPEPTIDES 
FEDERALLY SPONSORED RESEARCH AND 
DEVELOPMENT 
This invention was made with Government support under 
contract NAGS-1843 awarded by the NASA Marshall Space 
Flight Center. The Government has certain rights in this 
invention. 
BACKGROUND OF THE INVENTION 
Protein synthesis is a fundamental biological process that 
underlies the development of polypeptide therapeutics, diag-
nostics, and industrial enzymes. With the advent of recombi-
nant DNA (rDNA) technology, it has become possible to 
harness the catalytic machinery of the cell to produce a 
desired protein. This can be achieved within the cellular envi-
ronment or in vitro using extracts derived from cells. 
Cell-free protein synthesis offers several advantages over 
in vivo protein expression methods. Cell-free systems can 
direct most, if not all, of the metabolic resources of the cell 
towards the exclusive production of one protein. Moreover, 
the lack of a cell wall in vitro is advantageous since it allows 
for control of the synthesis environment. For example, tRNA 
levels can be changed to reflect the codon usage of genes 
being expressed. The redox potential, pH, or ionic strength 
can also be altered with greater flexibility than in vivo since 
we are not concerned about cell growth or viability. Further-
more, direct recovery of purified, properly folded protein 
products can be easily achieved. 
In vitro translation is also recognized for its ability to 
incorporate unnatural and isotope-labeled amino acids as 
well as its capability to produce proteins that are unstable, 
insoluble, or cytotoxic in vivo. In addition, cell-free protein 
synthesis may play a role in revolutionizing protein engineer-
ing and proteomic screening technologies. The cell-free 
method bypasses the laborious processes required for cloning 
and transforming cells for the expression of new gene prod-
ucts in vivo, and is becoming a platform technology for this 
field. 
Among the proteins of interest for cell-free synthesis, 
many either span or are anchored to membranes. These pro-
teins and other biomolecules incorporated into membranes 
surrounding cells and organelles moderate a wide variety of 
cellular functions. Furthermore, many lipids and glycolipids 
are targets for, or activate, protein functions. 
For example, about half of potential pharmaceutical targets 
are membrane proteins, e.g. ion channels and G protein 
coupled receptors, which have been difficult to utilize in drug 
screening and design assays. Because of their location in 
membranes, these proteins are frequently difficult to purify 
and characterize. They are also difficult to obtain in large 
quantities, and recombinant DNA methods often fail to pro-
vide large amounts of properly folded membrane proteins, in 
part because overexpression of membrane proteins is gener-
ally toxic to living cells, thus limiting the yield. 
To avoid this toxicity, in vitro techniques have been 
attempted to produce higher yields of protein. However, 
reports have shown either low yields, similar or less than 
those obtained in vivo; high yields, but where most of the 
protein is aggregated and must be refolded post-translation-
ally; or high yields where the protein has been synthesized 
into detergents or lipo somes without using the natural folding 
pathway, raising a question of whether these systems produce 
membrane proteins that are authentically folded. 
2 
One of the major limitations in studying membrane pro-
teins has been the general difficulty in producing significant 
quantities of correctly folded protein. The present invention 
addresses this need. 
5 Relevant Literature 
U.S. Pat. No. 6,337,191 B1; Swartz et al. U.S. Patent Pub-
lished Application 20040209321; Swartz et al. International 
Published Application WO 2004/016778; Swartz et al. U.S. 
Patent Published Application 2005-0054032-A1; Swartz et 
to al. U.S. Patent Published Application 2005-0054044-A1; 
Swartz et al. International Published Application WO 2005/ 
052117. Calhoun and Swartz (2005) Biotechnol Bioeng 
90(5):606-13; Jewett and Swartz (2004) Biotechnol Bioeng 
15 86(1):19-26; Jewett et al. (2002) Prokaryotic Systems for In 
Vitro Expression. In: Weiner M, Lu Q, editors. Gene cloning 
and expression technologies. Westborough, Mass.: Eaton 
Publishing. p 391-411; Lin et al. (2005) Biotechnol Bioeng 
89(2): 148-56. 
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SUMMARY OF THE INVENTION 
Methods are provided for high yield cell-free synthesis of 
membrane associated proteins. In the methods of the inven- 
25 tion, vesicles are added to a cell-free synthesis reaction, pro-
viding for direct insertion of the nascent polypeptide into a 
biological membrane, thereby providing for folding in a 
membrane environment. Generally the synthesis is per-
formed as a coupled transcription and translation reaction to 
30 allow for co-translational folding. These methods provide for 
high yields of active protein. The method may further include 
the isolation of the synthesized protein in a membrane bound 
state. 
In some embodiments, the methods of the invention further 
35 include providing signal recognition particles (SRP) to the 
reaction. The particles may be exogenously produced, or 
co-synthesized in the reaction mix. A docking protein for the 
SRP may also be included. 
In a preferred embodiment, the synthesis reaction condi- 
40 tions provide for in vitro activation of oxidative phosphory-
lation. The activation of oxidative phosphorylation may be 
evidenced by the ability of the reaction mixture to regenerate 
ATP in the absence of conventional secondary energy 
sources. The activation of oxidative phosphorylation can also 
45 be demonstrated by the sensitivity of the reaction mixture to 
specific inhibitors of this pathway. Such reactions are sub-
stantially free of polyethylene glycol. 
Production of high yields of active membrane associated 
proteins is useful in a variety of methods, including screening 
50 for drug candidates that interact with pharmacologically rel-
evant membrane protein targets such as multi-drug transport-
ers or signaling proteins; development of membrane protein-
based biosensors; strategies for detoxification wherein the 
vesicles import toxins for subsequent vesicle recovery and 
55 removal; and the like. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 Total and dialyzed protein yields from cell-free 
6o reactions synthesizing Mt1A or TetA. 
FIG. 2 (a) Topology of Mt1A showing six transmembrane 
segments and a large C-terminal domain on the cytoplasmic 
side of the membrane. (b) Predicted topology of the trans-
membrane portion of MtIA. The largest cytoplasmic loop 
65 (K185-V273) encompasses 89 amino acids. 
FIG. 3 Coomassie stained protein gel (left) and corre-
sponding autoradiogram (right) of Mt1A samples digested at 
US 8,183,010 B2 
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37° C. with Proteinase K. Abbreviations: Proteinase K (Prot 
K), lithium dodecyl sulfate (LDS). 
FIG. 4 Topology of TetA showing twelve transmembrane 
segments. The largest cytoplasmic loop (Ml S 1-A213) is only 
33 amino acids. 
FIG. 5 Coomassie stained protein gel (right) and corre-
sponding autoradiogram (left) of TetA samples digested at 
25° C. with Proteinase K. Abbreviations: Proteinase K (Prot 
K), lithium dodecyl sulfate (LDS). 
FIG. 6 Tetracycline accumulation inside vesicles present 
during TetA or CAT protein expression. 
FIG. 7 Schematic of the sucrose flotation assay. 
FIG. 8 Distribution of radiolabeled Mt1A in sucrose floata-
tion assays. Vesicle-associated Mt1A floats up to fraction 2, 
while aggregated Mt1A remains at the bottom of the gradient 
in fractions 6-8. 
FIG. 9 Distribution of radiolabeled TetA in sucrose flota-
tion assays. Vesicle-associated TetA floats up to fraction 2, 
while aggregated TetA remains at the bottom of the gradient 
in fractions 5-7. 6M urea is added to remove TetA that is 
non-specifically associated with the vesicles. 
FIG. 10. Distribution of radiolabeled AgpZ in sucrose 
floatation assays. Vesicle-associated AgpZ floats up to frac-
tion 2, while aggregated AgpZ remains at the bottom of the 
gradient in fractions 5-7. 
FIG. 11. Autoradiogram of AgpZ samples digested at 37° 
C. with Proteinase K. Abbreviations: Proteinase K (Prot K), 
lithium dodecyl sulfate (LDS). 
FIG. 12. Rayleigh light scattering measurements monitor-
ing water transport out of vesicles in a hyper -tonic environ-
ment. Vesicles containing synthesized AgpZ show a faster 
rate of vesicle shrinkage than control vesicles obtained from 
a control reaction in which an unrelated protein, chloram-
phenicol acetyl transferase (CAT), was produced. 
DETAILED DESCRIPTION OF THE 
EMBODIMENTS 
4 
will be at least about 5% that of the native protein, usually at 
least about 10% that of the native protein, and may be about 
25%, about 50%, about 90% or greater. 
One aspect of the high yield is that the proteins are directly 
5 inserted into membranes during synthesis. Therefore the iso-
lation of active membrane associated protein does not require 
the use of artificial lipo somes, or refolding of the protein. The 
protein may be directly isolated from the reaction mixture in 
any method that preserves the membrane association. Meth- 
10 ods of protein purification that maintain membrane integrity 
are known in the art. Typically, mild detergents such as laurel 
glucosides or maltosides are used to distribute the properly 
folded membrane spanning proteins into micelles containing 
one or only a few protein molecules. These micelles are then 
15 separated based on their protein cargoes to provide purified 
membrane spanning proteins (see Loll, P 7, J. of Structural 
Biology, 142:144-153; 2003), herein specifically incorpo-
rated by reference. 
In some embodiments, the methods of the invention further 
20 include providing signal recognition particles (SRP) to the 
reaction. The particles may be exogenously produced, or 
co-synthesized in the reaction mix. Docking protein (SR) 
may also be included. 
Activation of oxidative phosphorylation is obtained by a 
25 combination of reaction conditions, which conditions may 
include, without limitation, the use of biological extracts 
derived from bacteria grown on a glucose containing 
medium; an absence of polyethylene glycol; and optimized 
magnesium concentration. The system does not require the 
30 addition of commonly used secondary energy sources, which 
energy sources typically contain high energy phosphate 
bonds, such as phosphoenolpyruvate, creatine phosphate, 
acetyl phosphate, glucose-6-phosphate, pyruvate or glyco-
lytic intermediates. The reaction may be further improved by 
35 employing ions and compounds in the cell-free reaction mix- 
ture that are commonly found in the E. coli cytoplasm. 
Definitions 
High yield synthesis of membrane-associated proteins is 
accomplished by performing coupled transcription and trans-  40 	 It is to be understood that this invention is not limited to the 
lation reactions in a cell-free reaction, where membrane 	 particular methodology, protocols, cell lines, animal species 
vesicles are present, and where the reaction conditions pro- 	 or genera, and reagents described, as such may vary. It is also 
vide for in vitro activation of oxidative phosphorylation. The 	 to be understood that the terminology used herein is for the 
protein of interest is synthesized in a manner that allows 	 purpose of describing particular embodiments only, and is not 
co-translational folding and direct insertion of the nascent 45 intended to limit the scope of the present invention, which 
polypeptide into a membrane, thereby providing for folding 	 will be limited only by the appended claims. 
in a membrane environment. The method may further include 	 As used herein the singular forms "a", "and", and "the" 
the isolation of the synthesized protein in a membrane bound 
	
include plural referents unless the context clearly dictates 
state. 	 otherwise. Thus, for example, reference to "a cell' includes a 
The methods of the invention provide for high yields of 50 plurality of such cells and reference to "the culture" includes 
active protein, which may be greater than the yield that can be 	 reference to one or more cultures and equivalents thereof 
achieved with in vivo expression systems. In one embodiment 	 known to those skilled in the art, and so forth. All technical 
of the invention, the yield of active membrane associated 	 and scientific terms used herein have the same meaning as 
protein is greater than the yield of the protein of interest in 	 commonly understood to one of ordinary skill in the art to 
vivo. In other aspects, the yield of active membrane-associ-  55 which this invention belongs unless clearly indicated other-
ated protein is at least about 50 µg/ml of reaction mixture; at 	 wise. 
least about 100 µg/ml of reaction mixture; at least about 250 
	
The terms "desired protein" or "selected protein" are used 
µg/ml of reaction mixture; or more. 	 interchangeably and refer generally to any peptide or protein 
The methods of the present invention provide for mem- 	 having more than about 5 amino acids, which is membrane 
brane associated proteins that have biological activity com-  6o associated by virtue of a membrane inserted polypeptide. The 
parable to the native protein. One may determine the specific 	 polypeptides may be homologous to, or preferably, may be 
activity of a protein in a composition by determining the level 	 exogenous, meaning that they are heterologous, i.e., foreign, 
of activity in a functional assay, quantitating the amount of 	 to the bacteria from which the bacterial cell-free extract is 
protein present in a non-functional assay, e.g. immunostain- 	 derived, such as a human protein or a yeast protein produced 
ing, ELISA, quantitation on coomasie or silver stained gel, 65 in the bacterial cell-free extract. 
etc., and determining the ratio of biologically active protein to 	 Membrane associated proteins. Membrane proteins can be 
total protein. Generally, the specific activity as thus defined 	 classified into two broad categories, integral (intrinsic) and 
US 8,183,010 B2 
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peripheral (extrinsic), based on the nature of the membrane- 	 of skill in the art will appreciate that many culture media can 
	
protein interactions. For the purposes of the present inven- 	 be adapted for this purpose, as there are many published 
	
tion, membrane associated proteins are typically integral 	 media suitable for the growth of bacteria such as E. coli, using 
	
membrane proteins, also called intrinsic proteins, which have 	 both defined and undefined sources of nutrients (see Sam- 
one or more segments that are embedded in the phospholipid 5 brook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular 
	
bilayer. Most integral proteins contain residues with hydro- 	 Cloning: A Laboratory Manual, 2" d edition. Cold Spring Har- 
	
phobic side chains that interact with fatty acyl groups of the 	 bor University Press, Cold Spring Harbor, N.Y. for examples 
	
membrane phospholipids, thus anchoring the protein to the 	 of glucose containing media). Alternatively, the culture may 
	
membrane. Most integral proteins span the entire phospho- 	 be grown using a protocol in which the glucose is continually 
lipid bilayer. These transmembrane proteins contain one or io fed as required to maintain a high growth rate in either a 
	
more membrane-spanning domains as well as domains, from 	 defined or complex growth medium. 
	
four to several hundred residues long, extending into the 	 Another important change in the reaction mixture is the 
aqueous medium on each side of the bilayer. 	 substantial absence of polyethylene glycol (PEG). A conven- 
	
Some proteins are bound only to the membrane surface, 	 tional reaction mixture (for example, see Kim and Swartz, 
whereas others have one region buried within the membrane 15 2001) contains about 2% polyethylene glycol 8000. However 
	
and domains on one orboth sides of it. Protein domains on the 	 it is found that this diminishes the yield. Typically PEG will 
	
extracellular membrane surface are generally involved in 	 be present in not more than trace amounts, for example less 
	
cell-cell signaling or interactions. Domains within the mem- 	 than 0.1%, and may be less than 0.01%. In the present meth- 
	
brane, particularly those that form channels and pores, move 	 ods, the molecules spermidine and putrescine are used in the 
molecules across the membrane. Domains lying along the 20 place of PEG. Spennine or spermidine is present at a concen- 
	
cytosolic face of the membrane have a wide range of func- 	 tration of at least about 0.5 mM, usually at least about 1 mM, 
	
tions, from anchoring cytoskeletal proteins to the membrane 	 preferably about 1.5 mM, and not more than about 2.5 mM. 
to triggering intracellular signaling pathways. 	 Putrescine is present at a concentration of at least about 0.5 
G protein-coupled receptors are integral membrane pro-  mM, preferably at least about 1 mM, preferably about 1.5 
teins that possess seven membrane-spanning domains or 25 mM, and not more than about 2.5 mM. The spermidine and/or 
transmembrane helices. The extracellular parts of the recep-  putrescine may be present in the initial cell extract or may be 
	
tor can be glycosylated. These extracellular loops also con- 	 separately added. 
	
tain two highly conserved cysteine residues which build dis- 	 The concentration of magnesium in the reaction mixture 
	
ulfide bonds to stabilize the receptor structure. Some seven 	 affects the overall synthesis. Often there is magnesium 
transmemebrane helix proteins that resemble G proteins may 30 present in the cell extracts, which may then be adjusted with 
	
contain different functional groups, such as entire ion chan- 	 additional magnesium to optimize the concentration. Sources 
	
nels, within their protein. While in other types of receptors 	 of magnesium salts useful in such methods are known in the 
	
that have been studied ligands bind externally to the mem- 	 art. In one embodiment of the invention, the source of mag- 
	
brane, the ligands of G-protein-coupled receptors typically 	 nesium is magnesium glutamate. A preferred concentration 
bind within the transmembrane domain. 	 35 of magnesium is at least about 5 mM, usually at least about 10 
	
Another important class of membrane-associated proteins 	 mM, and preferably a least about 12 mM; and at a concentra- 
	
are ion channels. All ion channels are complexes of trans- 	 tion of not more than about 20 mM, usually not more than 
	
membrane proteins, sometimes they contain cytoplasmic 	 about 15 mM. Other changes that may enhance synthesis 
	
subunits, often they are glycosylated. Ion channels can be 	 include the omission of HEPES buffer and phosphoenol pyru- 
classified according to which chemical or physical modulator 40 vate from the reaction mixture. 
	
controls their gating activity. Thus we have different groups 	 The system can be run under aerobic and anaerobic condi- 
	
of channels, including: ligand gated channels/neurotransmit- 	 tions. Oxygen may be supplied, particularly for reactions 
	
ters; voltage gated channels/transmembrane potential (elec- 	 larger than 15 µl, in order to increase synthesis yields. The 
	
tric field); second messenger gated channels/nucleotides, 	 headspace of the reaction chamber can be filled with oxygen; 
G-proteins; mechano sensitive channels/osmotic pressure or 45 oxygen may be infused into the reaction mixture; etc. Oxygen 
	
membrane curvature; gap junctions, porins/not gated. Chan- 	 can be supplied continuously or the headspace of the reaction 
	
nels are also ion selective. They can discriminate between 	 chamber can be refilled during the course of protein expres- 
size and charge of the permeant molecule. 	 sion for longer reaction times. Other electron acceptors, such 
In vitro synthesis, as used herein, refers to the cell-free as nitrate, sulfate, or fumarate may also be supplied in con-
synthesis of polypeptides in a reaction mix comprising bio-  50 junction with preparing cell extracts so that the required 
logical extracts and/or defined reagents. The reaction mix will enzymes are active in the cell extract. 
	
comprise a template for production of the macromolecule, 	 It is not necessary to add exogenous cofactors for activation 
	
e.g. DNA, mRNA, etc.; monomers for the macromolecule to 	 of oxidative phosphorylation. Compounds such as nicotina- 
	
be synthesized, e.g. amino acids, nucleotides, etc., and such 	 mide adenine dinucleotide (NADH), NAD+, or acetyl-coen- 
co-factors, enzymes and other reagents that are necessary for 55 zyme A may be used to supplement protein synthesis yields 
	
the synthesis, e.g. ribosomes, tRNA, polymerases, transcrip- 	 but are not required. Addition of oxalic acid, a metabolic 
	
tional factors, etc. Such synthetic reaction systems are well- 	 inhibitor of phosphoenolpyruvate synthetase (Pps), may be 
	
known in the art, and have been described in the literature. 	 beneficial in increasing protein yields, but is not necessary. 
	
The cell free synthesis reaction may be performed as batch, 	 The template for cell-free protein synthesis can be either 
continuous flow, or semi-continuous flow, as known in the art. 60 mRNA or DNA, preferably a combined system continuously 
	
The Cytomin"m environment for synthesis utilizes cell 	 generates mRNA from a DNA template with a recognizable 
	
extracts derived from bacterial cells grown in medium con- 	 promoter. Either endogenous RNA polymerase is used, or an 
	
taining glucose and phosphate, where the glucose is present 	 exogenous phage RNA polymerase, typically T7 or SP6, is 
	
initially at a concentration of at least about 0.25% (weight/ 	 added directly to the reaction mixture. Alternatively, mRNA 
volume), more usually at least about 1%; and usually not 65 can be continually amplified by inserting the message into a 
	
more than about 4%, more usually not more than about 2%. 	 template for QB replicase, an RNA dependent RNA poly- 
	
An example of such media is 2YTPG medium, however one 	 merase. Purified mRNA is generally stabilized by chemical 
US 8,183,010 B2 
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8 
modification before it is added to the reaction mixture. 	 protein may also be co-expressed. Co-expression may be 
Nucleases can be removed from extracts to help stabilize 	 sequential or simultaneous. Alternatively, these components 
mRNA levels. The template can encode for any particular 	 may be produced and isolated from in vitro or in vivo expres- 
gene of interest. 	 sion, and added to the mixture; or may be over-produced in 
Other salts, particularly those that are biologically relevant, 5 the bacteria from which the extracts are derived. 
such as manganese, may also be added. Potassium is gener- 	 Folding, as used herein, refers to the process of forming the 
ally present at a concentration of at least about 50 mM, and 	 three-dimensional structure of polypeptides and proteins, 
not more than about 250 mM. Ammonium may be present, 	 where interactions between amino acid residues act to stabi- 
usually at a concentration of not more than 200 mM, more 	 lize the structure. Non-covalent interactions are important in 
usually at a concentration of not more than about 100 mM. 10 determining structure, and the effect of membrane contacts 
Usually, the reaction is maintained in the range of about pH 	 with the protein are important for the correct structure. For 
5-10 and a temperature of about 20°-50° C.; more usually, in 	 naturally occurring proteins and polypeptides or derivatives 
the range of about pH 6-9 and a temperature of about 25'-40' 	 and variants thereof, the result of proper folding is typically 
C. These ranges may be extended for specific conditions of 	 the arrangement that results in optimal biological activity, and 
interest. 	 15 can conveniently be monitored by assays for activity, e.g. 
Metabolic inhibitors to undesirable enzymatic activity may 	 ligand binding, enzymatic activity, etc. 
be added to the reaction mixture. Alternatively, enzymes or 	 In some instances, for example where the desired product 
factors that are responsible for undesirable activity may be 	 is of synthetic origin, assays based on biological activity will 
removed directly from the extract or the gene encoding the 	 be less meaningful. The proper folding of such molecules 
undesirable enzyme may be inactivated or deleted from the 20 may be determined on the basis of physical properties, ener-
chromosome. 	 getic considerations, modeling studies, and the like. 
Vesicles are added to the reaction mix. Vesicles may puri- 	 The synthesis of membrane-associated protein may be fol- 
fied from the organism from which the extract is derived (see 	 lowed by direct isolation of the active, membrane associated 
Muller and Blobel (1984) "In vitro translocation of bacterial 	 forms, i.e. in the absence of refolding or post-translational 
proteins across the plasma membrane of Escherichia coli", 25 introduction of membranes. The separation procedure will 
PNAS 81:7421-7425); or isolated from any other suitable 	 utilize conditions that maintain membrane integrity, as is 
cell, e.g. mammalian cells including cells from the species of 	 known in the art. 
target protein; or synthetic. Vesicles are typically added at a 	 Separation procedures of interest include affinity chroma- 
concentration of 0.1 to 5 mg/ml lipids, more preferably about 	 tography. Affinity chromatography makes use of the highly 
0.4 to 2.5 mg/ml. Vesicles may be purified by sucrose density 30 specific binding sites usually present in biological macromol- 
gradient centrifugation or by other means known in the art. 	 ecules, separating molecules on their ability to bind a particu- 
Vesicle preparation methods include, without limitation: 	 lar ligand. Covalent bonds attach the ligand to an insoluble, 
homogenization, French press, extrusion, freeze/thaw, soni- 	 porous support medium in a manner that overtly presents the 
cation, osmotic lysis, lysozyme/EDTA treatment, and the 	 ligand to the protein sample, thereby using natural biospecific 
like. Other components that affect membrane protein inser-  35 binding of one molecular species to separate and purify a 
tion or folding may be added to the cell-free reaction mixture, 	 second species from a mixture. Antibodies are commonly 
including SRP, Ffh, 4.5S RNA, FtsY, and SecA. 	 used in affinity chromatography. Preferably a microsphere or 
Signal recognition particle. Co-translational targeting of 	 matrix is used as the support for affinity chromatography. 
secretory and membrane proteins to the prokaryotic plasma 	 Such supports are known in the art and are commercially 
membrane or eukaryotic endoplasmic reticulum is mediated 40 available, and include activated supports that can be coupled 
by a ribonucleoprotein complex, the signal recognition par- 	 to the linker molecules. For example, Affi-Gel supports, 
ticle (SRP), and its membrane-associated receptor (SR). SRP 	 based on agarose or polyacrylamide are low pressure gels 
binds to signal sequences of nascent proteins as they emerge 	 suitable for most laboratory-scale purifications with a peri- 
from the exit tunnel of the ribosome. The resulting targeting 	 staltic pump or gravity flow elution. Affi-Prep supports, based 
complex, composed of the SRP and the ribosome-nascent 45 on a pressure-stable macroporous polymer, are suitable for 
chain complex (RNC), then docks with the SR in a GTP- 	 preparative and process scale applications. 
dependent manner. Passing through a complex series of con- 	 Proteins may also be separated by ion exchange chroma- 
formational states, SRP and SR deliver the RNC to the trans- 	 tography, and/or concentrated, filtered, dialyzed, etc., using 
locon, which in turn mediates protein translocation across or 	 methods known in the art. 
integration into the membrane. As translocation proceeds, the 50 
signal sequence may be cleaved by signal protease and the 	 Methods For Synthesis 
polypeptide released into the ER lumen. Alternatively, the 
protein can insert into the membrane to form a membrane 	 The reactions may utilize a large scale reactor, small scale, 
spanning protein. 	 or may be multiplexed to perform a plurality of simultaneous 
The bacterial SRP has a simple composition as compared 55 syntheses. Continuous reactions will use a feed mechanism to 
to its eukaryotic counterpart. It contains only a single protein 	 introduce a flow of reagents, and may isolate the end-product 
homologous to SRP54 (termed Ffh) and a single RNA mol- 	 as part of the process. Batch systems are also of interest, 
ecule, between 80 and 200 nts in size, e.g. a 110-nucleotide 	 where additional reagents may be introduced to prolong the 
4.5S RNA in E. coli. In bacteria and archaea, SRs are single- 	 period of time for active synthesis. A reactor may be run in 
subunit proteins, also named FtsY. Bacterial SRs are periph-  6o any mode such as batch, extended batch, semi-batch, semi- 
erally associated with membranes. 	 continuous, fed-batch and continuous, and which will be 
The SRP and docking protein (SR) are optionally included 	 selected in accordance with the application purpose. 
in the reaction mix for the methods of the invention. These 	 The reactions may be of any volume, either in a small scale, 
may be provided through co-expression of the components in 	 usually at least about 1 µl and not more than about 15 µl, or in 
the reaction mix, or through exogenous addition. Where the 65 a scaled up reaction, where the reaction volume is at least 
components are provided by co-expression, a vector encod- 	 about 15 µl, usually at least about 50 µl, more usually at least 
ing the Ffh protein and the 4.5S RNA are provided. The FtsY 	 about 100 µl, and may be 500 µl, 1000 µl, or greater. In most 
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cases, individual reactions will not be more than about 10 ml, 
although multiple reactions can be run in parallel. However, 
in principle, reactions may be conducted at any scale as long 
as sufficient oxygen (or other electron acceptor) is supplied 
when needed. 5 
In addition to the above components such as cell-free 
extract, genetic template, and amino acids, materials specifi-
cally required for protein synthesis may be added to the 
reaction. These materials include salt, folinic acid, cyclic 
AMP, inhibitors for protein or nucleic acid degrading io 
enzymes, inhibitors or regulators of protein synthesis, adjust-
ers of oxidation/reduction potential(s), non-denaturing sur-
factants, buffer components, spermine, spermidine, 
putrescine, etc. 
The salts preferably include potassium, magnesium, and 15 
ammonium salts (e.g. of acetic acid or sulfuric acid). One or 
more of such salts may have amino acids as a counter anion. 
There is an interdependence among ionic species for optimal 
concentration. These ionic species are typically optimized 
with regard to protein production. When changing the con- 20 
centration of a particular component of the reaction medium, 
that of another component may be changed accordingly. For 
example, the concentrations of several components such as 
nucleotides and energy source compounds may be simulta-
neously adjusted in accordance with the change in those of 25 
other components. Also, the concentration levels of compo-
nents in the reactor may be varied over time. The adjuster of 
oxidation/reduction potential may be dithiothreitol, ascorbic 
acid, glutathione and/or their oxidized forms. 
In a semi-continuous operation mode, the outside or outer 30 
surface of the membrane is put into contact with predeter-
mined solutions that are cyclically changed in a predeter-
mined order. These solutions contain substrates such as 
amino acids and nucleotides. At this time, the reactor is oper-
ated in dialysis, diafiltration batch or fed-batch mode. A feed 35 
solution may be supplied to the reactor through the same 
membrane or a separate injection unit. Synthesized protein is 
accumulated in the reactor, and then is isolated and purified 
according to the usual method for protein purification after 
completion of the system operation. Vesicles containing the 40 
product may also be continuously isolated, for example by 
affinity adsorption from the reaction mixture either in situ or 
in a circulation loop as the reaction fluid is pumped past the 
adsorption matrix. 
Where there is a flow of reagents, the direction of liquid 45 
flow can be perpendicular and/or tangential to a membrane. 
Tangential flow is effective forrecyclingATP and forprevent-
ing membrane plugging and may be superimposed on per-
pendicular flow. Flow perpendicular to the membrane may be 
caused or effected by a positive pressure pump or a vacuum 50 
suction pump or by applying transmembrane pressure using 
other methods known in the art. The solution in contact with 
the outside surface of the membrane may be cyclically 
changed, and may be in a steady tangential flow with respect 
to the membrane. The reactor may be stirred internally or 55 
externally by proper agitation means. 
During protein synthesis in the reactor, the protein isolat-
ing means for selectively isolating the desired protein may 
include a unit packed with particles coated with antibody 
molecules or other molecules immobilized with a component 60 
for adsorbing the synthesized, desired protein. Preferably, the 
protein isolating means comprises two columns for alternat-
ing use. 
The amount of protein produced in a translation reaction 
can be measured in various fashions. One method relies on the 65 
availability of an assay which measures the activity of the 
particular protein being translated. An example of an assay  
10 
for measuring protein activity is a luciferase assay system, or 
chloramphenical acetyl transferase assay system. These 
assays measure the amount of functionally active protein 
produced from the translation reaction. Activity assays will 
not measure full length protein that is inactive due to 
improper protein folding or lack of other post translational 
modifications necessary for protein activity. 
Another method of measuring the amount of protein pro-
duced in coupled in vitro transcription and translation reac-
tions is to perform the reactions using a known quantity of 
radiolabeled amino acid such as 31 S-methionine, 3 H-leucine 
or 14C-leucine and subsequently measuring the amount of 
radiolabeled amino acid incorporated into the newly trans-
lated protein. Incorporation assays will measure the amount 
of radiolabeled amino acids in all proteins produced in an in 
vitro translation reaction including truncated protein prod-
ucts. The radiolabeled protein may be further separated on a 
protein gel, and by autoradiography confirmed that the prod-
uct is the proper size and that secondary protein products have 
not been produced. 
Kits for the practice of the subject methods may also be 
provided. Such kits may include bacterial extracts for protein 
synthesis, buffers appropriate for reactions where oxidative 
phosphorylation is activated, and vesicles. Kits may also 
include vectors for protein synthesis, including vectors for 
expression of SRP and SR proteins; where the vectors may 
comprise promoter systems useful in bacterial extracts. 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how to make and use the subject invention, and 
are not intended to limit the scope of what is regarded as the 
invention. Efforts have been made to ensure accuracy with 
respect to the numbers used (e.g. amounts, temperature, con-
centrations, etc.) but some experimental errors and deviations 
should be allowed for. Unless otherwise indicated, parts are 
parts by weight, molecular weight is average molecular 
weight, temperature is in degrees centigrade; and pressure is 
at or near atmospheric. 
EXPERIMENTAL 
Example 1 
The protein synthesis reaction for these examples uses the 
CytoMimTM protocol described in WO 2004/016778, herein 
specifically incorporated by reference, with slight modifica-
tions. The components of this reaction include 13.3 µg/mL 
template plasmid, 1.2 mM AMP, 0.86 mM CMP, 0.86 mM 
GMP, 0.86 mM UMP, 34 µg/mL folinic acid, 170.6 µg/mL E. 
coli tRNA mixture, 2 mM each of 20 unlabeled amino acids, 
0.33 mM nicotinamide adenine dinucleotide, 0.27 mM coen-
zyme A, 1 mMputrescine, 1.5 mM spermidine, 4 mM sodium 
oxalate, 1 mM dithiothreitol, 10 mM ammonium glutamate, 
130 mM potassium glutamate, 8 mM magnesium glutamate, 
10 mM potassium phosphate pH 7.2, 12 µM [ 14C] -leucine, 
0.1 mg/mL T7 RNA polymerase, 0.24 volumes of E. coli S30 
extract, and 0.41 volumes of vesicle solution (detailed 
below). T7 RNA polymerase is prepared as described by 
Grodberg and Dunn (J of Bacteriology, 170:1245-1253; 
1988). E. coli S30 extract is prepared from the strain KC6 
(A19 AtonA AtnaA AspeA AendA AsdaA AsdaB AgsbA 
met*) (Calhoun and Swartz, Biotechnology Progress 2005. 
21 (4): p. 1146-53) grown according to Zawada, et al. in 
Fermentation Biotechnology, B. Saba, Editor. 2003, Ameri-
can Chemical Society: Washington, D.C. p. 142-156, and 
prepared according to Jewett, et al. in Gene Cloning and 
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Expression Technologies, M. Weiner and Q. Lu, Editors. 	 sulfate (LDS) detergent which dissolves membranes, the 
2002, Eaton Publishing: Westborough, Mass. p. 391-411. 	 Mt1A bands are no longer protected from digestion; indicat- 
The vesicle solution is prepared using a method adapted 
	
ing that the protected bands are dependent on the presence of 
from Muller and Blobel (1984) Proc Natl Acad Sci U S A, 81 	 intact vesicle membranes. Thus, the observed band pattern 
(23): p. 7421-5, and Osborn, et al (1972) J Biol Chem, 1972. 5 demonstrates that a significant portion of the Mt1A is properly 
247 (12): p. 3962-72. KC6 cells are resuspended and washed 	 folded in the vesicle membranes. 
in 20 mM Tris-HCl pH 8.0, 1 mM EDTA. The final cell pellet 	 A similar analysis was performed with TetA. The topology 
is resuspended in 1 mL of the same buffer per gram of cells 	 of TetA, shown in FIG. 4, does not contain any large cyto- 
and incubated on ice with 0.2 mg/mL of lysozyme for 15 min. 	 plasmic domains or loops. Therefore, we focused on protec- 
After incubation, the cell solution is passed through anAves-  io tion of the full-length TetA. FIG. 5 shows the band profile 
tin homogenizer three times at 20000 psi. Unbroken cells and 	 obtained after incubation with Proteinase K at 25° C. Even 
debris are removed by two centrifugations at 30000xg for 20 	 after 60 min, a significant fraction of full-length TetA is still 
min each. Then the vesicles are collected by ultracentrifuga- 	 present in the vesicles. However, if the membranes are dis- 
tion (154000xg, 1.5 hr), and pelleted again through 0.5 	 solved with LDS detergent, the TetA is no longer protected 
mLlg C,,, of a solution containing 250 mM sucrose in buffer H 15 from digestion. Thus, it appears that the TetA is embedded 
(20 mM HEPES-KOH pH 7.5, 1 mM DTT, 5 mM EDTA) at 	 into the vesicle membranes. 
231000xg for 1 hr. These crudely purified vesicles are resus- 	 To further demonstrate that the TetA is properly folded, 
pended in 20% (w/w) sucrose in buffer H and loaded on top of 	 activity of the TetA protein was assayed. TetA is a proton- 
a step gradient containing layers of 50%, 45%, 40%, 35%, 	 antiporter, using a proton gradient to drive transport of a 
30%, and 25% (w/w) sucrose in buffer H. After ultracentrifu-  20 metal-tetracycline complex across the membrane. To assay 
gation for 24 hrs at 114000xg, the fractions containing inner 	 for TetA activity, first the TetA-containing vesicles were 
membrane vesicles (as detailed in Spencer et al. (1974) J 	 exposed to 13.3 mM NADH for 1 min at 37° C. in order to 
Bacteriol, 117 (3): p. 947-53, or Langley et al. (1982) J 	 generate a proton gradient across the vesicle membrane. 10 
Bacteriol, 152 (3): p. 1033-41) are collected. These vesicles 	 µM [3 H]-tetracycline and 0.5 mM cobalt chloride were then 
are pelleted by ultracentrifugation at 231,000xg for 1 hr and 25 added, and the reaction was further incubated for the times 
finally resuspended to high concentration (1-2 mg/mL) in 20 	 indicated in FIG. 6. The reactions are finally filtered and 
mM HEPES-KOH pH 7.2, 60 mM KCl, 1 mM DTT. 	 washed through a 30K molecular weight centrifugal filter to 
The membrane proteins mannitol permease (Mt1A) and the 	 separate vesicle-associated tetracycline from free tetracy- 
tetracycline pump (TetA) were synthesized by the methods of 	 cline in solution. FIG. 6 shows that more tetracycline accu- 
the invention. The plasmids pK7Mt1A and pK7TetA, respec-  30 mulates within vesicles containing TetA, as compared to con- 
tively, were used as templates encoding the genes under the 	 trol vesicles obtained from a cell-free reaction producing the 
control of T7 promoters. 	 unrelated soluble protein chloramphenicol acetyl transferase 
After 6 hrs of synthesis at 37° C., the synthesized protein 	 (CAT). The control vesicles show tetracycline accumulation 
was quantified by measuring TCA-precipitable radioactivity 	 of approximately 3-13 µM within the vesicles, which is con- 
using a liquid scintillation counter. FIG. 1 shows the total 35 sistent with equilibrium driven diffusion of tetracycline 
amount of Mt1A and TetA produced during the cell-free reac- 	 across the lipid membrane. The vesicles containing TetA, 
tion. Before further analysis, the reaction was crudely puri- 	 however, are able to accumulate tetracycline even against a 
fied by dialysis with a 100 kDa MWCO dialysis bag against 	 tetracycline concentration gradient, indicating that a signifi- 
500-1000 volumes of 10 mM Tris-HCl pH 8.0, 100 mM KCl, 	 cant portion of TetA is properly folded and active in the 
exchanged three times for at least 3 hours each time. The 40 vesicles. 
results in FIG.1 show that virtually all the synthesized protein 	 To quantify the amount of protein inserted into the vesicles, 
is retained during dialysis. 	 the dialyzed cell-free reactions were subjected to a sucrose 
To determine if the synthesized protein was folded prop- 	 flotation assay. The dialyzed reaction is mixed with a dense 
erly in the vesicle membranes, we exposed the dialyzed reac- 	 sucrose solution and loaded at the bottom of a three step 
tion mixture to 0.2 µg/ltL of the non-specific protease, Pro-  45 sucrose gradient (see FIG. 7). The densities of the layers are 
teinase K. Portions of the membrane protein that are not 	 chosen such that, after ultracentrifugation (16 hrs, 237000x 
embedded in the membrane such as cytoplasmic domains 	 g), the misfolded protein aggregates (with density p-1.3 
or large loops between transmembrane segments are 	 g/mL) stay in the bottom layer while the lighter vesicles 
degraded more quickly by the protease as compared with 
	 (p-1.13-1.25 g/mL, depending on how much protein has been 
segments within the membrane or in the vesicle interior. 50 inserted) float to the interface above the second layer. FIG. 8 
Thus, by observing the protein fragments generated by Pro- 	 shows the distribution of radiolabeled Mt1A after sucrose 
teinase K digestion over time, we can verify whether the 	 floatation analysis. 6 M urea has been added throughout the 
protein has the expected topology that corresponds with 	 gradients to reduce non-specific association of the synthe- 
proper folding. 	 sized protein with membranes. When vesicles are present in 
Mt1A is well suited for protease digestion analysis because 55 the reaction, we see that 20% of the synthesized Mt1A is 
it contains a large cytoplasmic domain (FIG. 2a) as well as a 	 associated with the vesicles (fraction 2). This association 
large cytoplasmic loop (FIG. 2b). FIG. 3 shows digested 	 disappears when the vesicles are not added to the protein 
Mt1A after incubation with Proteinase K at 37° C. for 0 to 60 	 synthesis reaction, as indicated by the retention of aggregated 
min. During the early time points, a distinct band of approxi- 	 Mt1A in the lower fractions (fractions 6-8). The amount of 
mately 30 kDa is formed. This corresponds well with a frag-  60 Mt1A shown inserted into vesicles corresponds to an overall 
ment containing only the six transmembrane segments, after 	 yield of 60 µg of inserted Mt1A per mL of cell-free reaction, 
degradation of the large cytoplasmic domain. As the digestion 	 approximately 30 times the typical in vivo yields for Mt1A 
reaction proceeds, the 30 kDa band diminishes in favor of a 17 
	 (<2 µg/mL). 
kDa band. This 17 kDa band is comparable to the expected 
	
Even higher yields were obtained for TetA. FIG. 9 shows 
fragment containing four transmembrane segments, obtained 65 sucrose floatation profiles for reactions producing TetA. In 
after digestion of the large 89-amino acid cytoplasmic loop. If 	 the presence of vesicles, over 60% of the synthesized TetA is 
the reaction is performed in the presence of lithium dodecyl 	 associated with the vesicles (fraction 2). The addition of 6M 
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urea only slightly reduces this value, indicating that the TetA 	 nitol. This can be done either (a) by homogenizing cells in 
is specifically associated. When the vesicles are not added to 	 buffer containing mannitol during preparation of the vesicle 
the synthesis reaction, the TetA remains aggregated and local- 	 solution before cell-free synthesis of Mt1A or (b) by extruding 
izes in fractions 5-7 of the sucrose gradient. The amount of 
	
MtIA-containing vesicles after the cell-free reaction in buffer 
TetA shown inserted into vesicles corresponds to an overall 5 containing mannitol. After a crude purification by dialysis in 
yield of 440 µg of inserted TetA per mL of cell-free reaction, 	 a 100 kDa MWCO dialysis bag, any residual HPr (9 kDa) or 
approximately 300 times the typical in vivo yields for TetA 
	 Enzyme I (63 kDa) carried over from the cell extract is 
(1-1.5 µg/mL). 	 removed. 
These data demonstrate that high yields of membrane pro- 	 Known amounts of purified HPr, Enzyme I, and PEP are 
teins are synthesized by the methods of the invention, and the 10 added to the vesicles to initial transport of Mt1A out of the 
synthesized protein is inserted into vesicles and properly 	 vesicles. After incubation at 37° C. for specified time inter- 
folded. 	 vals, the vesicles are collected and washed using a 30 kD 
molecular weight centrifugal filter which separates vesicle- 
Example 2 	 encapsulated mannitol from free mannitol in solution. The 
15 encapsulated mannitol (afterreleaseby addition of detergent) 
TetA Activity Assay 	 or free mannitol is quantified by HPLC. Taking this data with 
the measurement of inserted protein from sucrose flotation 
The TetA activity assay is performed similarly to that 	 assays, the rate of transport per Mt1A molecule is calculated. 
described inYamaguchi, et al (1990) J Biol Chem, 265 (9): p. 	 To determine if our cell-free produced Mt1A is fully active, 
4809-13. TetA is a proton-antiporter, catalyzing the transport 20 similar techniques as described above for TetA to produce 
of a metal-tetracycine complex out of the cytoplasm using the 	 vesicles containing known amounts of in vivo produced Mt1A 
cell's natural proton gradient as the driving force. 	 are used. 
To assay for TetA activity, a proton gradient is generated 
across the vesicle membrane by exposing the TetA-contain- 	 Example 4 
ing vesicles to 13.3 mM NADH at 37° C. for a fixed amount 25 
of time. The generated pH gradient is quantified using a 	 Expression ofAguaporin 
self-quenching, pH-sensitive fluorescent dye, such as quina- 
crine (Yamaguchi et al., (199 1) FEBS Lett, 282 (2): p. 415-8.) 	 Using the methods described above, the membrane pro- 
This dye is membrane permeable in its neutral state, but 	 tein, aquaporin Z (AgpZ), is produced in high yields and 
becomes protonated at low pH causing it to be preferentially 30 inserted directly into E. coli inner membrane vesicles without 
trapped inside the vesicles after the gradient has been gener- 	 the use of detergents or refolding steps. 
ated. Since the dye is self-quenching, the amount of dye 	 AgpZ is a 24 kDa with six transmembrane segments that 
trapped in the vesicles is indicated by a overall drop in fluo- 	 serves as a water-specific channel in the inner membrane of E. 
rescence signal, thereby giving a quantifiable measure of the 	 coli (Ringler, P., et al., Structure of the water channel AgpZ 
pH inside the vesicles. 	 35 from Escherichia coli revealed by electron crystallography. 
After generation of the pH gradient, 10 µM [3 H]-tetracy- 	 Journal of Molecular Biology, 1999. 291 (5): p. 1181-1190). 
cline and 0.5 mM cobalt chloride is then added, and the 	 AgpZ was produced in a cytomim-based cell-free reaction, 
reaction is further incubated at 37° C. At specified time inter- 	 as described above, supplemented with up to 0.6 mg/mL 
vals, the transported tetracycline is measured by collecting 	 (based on lipid content) of purified inner membrane vesicles. 
the vesicles and washing using a 30 kD molecular weight 4o These reactions yielded about 650-800 µg/mL of total AgpZ. 
centrifugal filter which separates vesicle-associated tetracy- 	 To determine how much of this protein is associated with 
cline from free tetracycline in solution. The radioactive tet- 	 vesicles, we used sucrose floatation to separate the vesicles 
racycline remaining on the filters can then be quantified using 	 from any aggregatedAgpZ. FIG. 10 shows the distribution of 
a liquid scintillation counter. By combining this data with the 	 AgpZ in the sucrose gradient. The vesicles, having lower 
measurements of inserted protein from sucrose flotation 45 density, float up through the gradient (fraction 2) while the 
assays, the rate of tetracycline transport per TetA molecule 	 denser aggregates stay at the bottom (fractions 5-7). 6M urea 
per unit pH gradient is calculated. 	 is also present throughout each gradient to minimize non- 
To determine if cell-free produced TetA is fully active, the 	 specific association of unfolded protein with the vesicles. 
activity data is compared to vesicles made from E. coli strain 	 When vesicles are supplemented in the cell-free reaction, 
KC6 expressing TetA in vivo. The activity assay is performed 5o about 50% of the AgpZ is recovered in the vesicle fraction. 
with these vesicles as described above. In order to quantify 	 In contrast, a reaction in which vesicles are not added 
the number of TetA molecules in the cell-free vesicles, a 	 shows virtually all of theAgpZ remaining at the bottom of the 
fifteen amino acid tag is added to the TetA protein which is 	 gradient, presumably in an aggregated form. These results 
readily biotinylated by birA ligase (Avidity, LLC). After 	 show nearly 400 µg/mL of vesicle-associated AgpZ can be 
biotinylation, the vesicles are expo sed to radiolabeled strepta-  55 produced in the natural vesicles. This is over 150 times the 
vidin. By measuring the amount of bound streptavidin, the 	 typical yields obtained whenAgpZ is overexpressed in E. coli 
corresponding amount of TetA contained in the vesicles is 	 (Borgnia, M. J., et al., Functional reconstitution and charac- 
calculated. 	 terization of AgpZ, the E-coli water channel protein. Journal 
of Molecular Biology, 1999. 291 (5): p. 1169-1179). The 
Example 3 	 60 yield of vesicle-associated AgpZ in our cell-free system is 
similar to that seen with TetA. 
Mt1A Activity Assay 	 To determine if the vesicle-associated AgpZ is properly 
inserted, we subjected the protein to protease digestion. Prop- 
Mannitol transport by Mt1A is a PEP-driven process 	 erly folded AgpZ is known to be resistant to the protease 
involving two other cytoplasmic enzymes, HPr (heat stable, 65 Proteinase K, presumably protected by the surrounding lipid 
histidyl phosphorylatable protein) and PTS Enzyme I. To 	 membrane. FIG. 12 shows an autoradiogram in which radio- 
assay for Mt1A activity, the vesicles are preloaded with man- 	 labeled AgpZ is exposed to the protease for increasing dura- 
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tions. Even after one hour, a significant fraction of the full-
lengthAgpZ remains. In contrast, when the lipid membranes 
are dissolved using LDS detergent, the AgpZ is no longer 
protected, showing nearly complete degradation by 15 min. 
These results suggest that the associated AgpZ is properly 
inserted into the vesicle membrane. 
In addition to protease digestion, we also measured the 
activity of the produced AgpZ by measuring water transport 
using stopped-flow static light scattering (Haines, T. H., 
Water Transport across Biological-Membranes. Febs Letters, 
1994. 346 (1): p. 115-122). Vesicles containing the synthe-
sized AgpZ are extruded through a 50 nm membrane. The 
vesicle solution (0.05 mg/mL lipid basis) is then simulta-
neously injected into the flow chamber along with a 150 mM 
sucrose solution. The hypertonic environment causes the 
vesicles to shrink with time. The shrinkage rate can be moni-
tored by measuring the amount of Rayleigh light scattering 
that results (FIG. 12). Vesicles containing synthesized AgpZ 
show much faster shrinkage rates (time constant 7r-7 ms) than 
control vesicles in which an unrelated protein was produced 
(time constant X20 ms). From this data, we calculate a 
specific activity of 3.7x10-14 cm3/sec/monomer which 
matches the specific activities measured for in vivo produced 
AgpZ (2-10x10-14 cm3/sec/monomer (Pohl, P., et al., Highly 
selective water channel activity measured by voltage clamp: 
Analysis of planar lipid bilayers reconstituted with purified 
AgpZ. Proceedings of the National Academy of Sciences of 
the United States of America, 2001. 98 (17): p. 9624-9629). 
Thus, the AgpZ produced in our cell-free system is the same 
as that produced in vivo. 
It is to be understood that this invention is not limited to the 
particular methodology, protocols, cell lines, animal species 
or genera, constructs, and reagents described, as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only, and is not intended to limit the scope of 
the present invention, which will be limited only by the 
appended claims. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
to one of ordinary skill in the art to which this invention 
belongs. Although any methods, devices and materials simi-
lar or equivalent to those described herein can be used in the 
practice or testing of the invention, the preferred methods, 
devices and materials are now described. 
All publications mentioned herein are incorporated herein 
by reference for the purpose of describing and disclosing, for 
example, the cell lines, constructs, and methodologies that are 
described in the publications, which might be used in con-
nection with the presently described invention. The publica-
tions discussed above and throughout the text are provided 
solely for their disclosure prior to the filing date of the present 
application. Nothing herein is to be construed as an admission 
that the inventors are not entitled to antedate such disclosure 
by virtue of prior invention. 
What is claimed is: 
1. A method for synthesis of integral membrane associated 
polypeptides in a cell-free in vitro reaction, the method com-
prising: 
16 
synthesizing an integral membrane associated polypeptide 
in a cell-free in vitro translation reaction, where the 
reaction mixture comprises an extract from bacterial 
cells; components of polypeptide synthesis machinery; 
5 a template for transcription of mRNA and/or translation 
of said polypeptide; monomers for synthesis of said 
mRNA and/or polypeptides; and co-factors, enzymes 
and other reagents necessary for said transcription and/ 
or translation; and vesicles added to a concentration of at 
10 least 0.4 mg/ml lipids, wherein the reaction mix pro-
duces at least 50 µg/ml of said integral membrane asso-
ciated polypeptides. 
2. The method according to claim 1, wherein said reaction 
mixture produces at least 100 µg/ml of membrane associated 
15 polypeptide. 
3. A method for synthesis of integral membrane associated 
polypeptides in a cell-free in vitro reaction, the method com-
prising: 
synthesizing an integral membrane associated polypeptide 
20 in a cell-free in vitro translation reaction, where the 
reaction mixture comprises an extract from bacterial 
cells; components of polypeptide synthesis machinery; 
a template for transcription of mRNA and/or translation 
of said polypeptide; monomers for synthesis of said 
25 mRNA and/or polypeptides; and co-factors, enzymes 
and other reagents necessary for said transcription and/ 
or translation; and vesicles added to a concentration of at 
least 0.4 mg/ml lipids, wherein the reaction mix pro-
duces at least 50 µg/ml of integral membrane associated 
30 	 polypeptides; and 
isolating said integral membrane-associated polypeptide 
from said reaction mixture under conditions that main-
tain membrane association of said polypeptide and said 
vesicles. 
35 	 4. The method according to claim 1, wherein said reaction 
mixture comprises signal recognition particles (SRP). 
5. The method according to claim 4, wherein said reaction 
mixture further comprises FtsY protein. 
6. The method of claim 1 wherein said synthesis is per-
40 formed as a batch or fed-batch reaction. 
7. The method of claim 1, wherein said synthesis is per-
formed as a continuous reaction. 
8. The method of claim 1, wherein said reaction mix com-
prises an extract from E. coil grown in glucose containing 
45 medium. 
9. The method of claim 8, wherein said E. coil are grown in 
glucose and phosphate containing medium. 
10. The method of claim 5, wherein said reaction mix 
comprises magnesium at a concentration of from about 5 mM 
50 to about 20 mM. 
11. The method of claim 6, wherein said reaction mix is 
substantially free of polyethylene glycol. 
12. The method according to claim 7, wherein said reaction 
mix comprises one or more of spermine, spermidine and 
55 putrescine. 
13. The method of claim 1, wherein the vesicles are puri-
fied prior to addition to the reaction mixture. 
